The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Drug-induced liver injury: Interactions between drug properties and host factors
Open accessAbstract
Idiosyncratic drug-induced liver injury (DILI) is a common cause for drug withdrawal from the market and although infrequent, DILI can result in serious clinical outcomes including acute liver failure and the need for liver transplantation. Eliminating the iatrogenic "harm" caused by a therapeutic intent is a priority in patient care. However, identifying culprit drugs and individuals at risk for DILI remains challenging. Apart from genetic factors predisposing individuals at risk, the role of the drugs' physicochemical and toxicological properties and their interactions with host and environmental factors need to be considered. The influence of these factors on mechanisms involved in DILI is multi-layered. In this review, we summarize current knowledge on 1) drug properties associated with hepatotoxicity, 2) host factors considered to modify an individuals' risk for DILI and clinical phenotypes, and 3) drug-host interactions. We aim at clarifying knowledge gaps needed to be filled in as to improve risk stratification in patient care. We therefore broadly discuss relevant areas of future research. Emerging insight will stimulate new investigational approaches to facilitate the discovery of clinical DILI risk modifiers in the context of disease complexity and associated interactions with drug properties, and hence will be able to move towards safety personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A fast learning algorithm for deep belief nets
Hinton, G. E., Osindero, S., & Teh, Y.-W. (2006) · Neural Computation · doi:10.1162/neco.2006.18.7.1527 · Cited by 16,336
Free radicals, oxidative stress, and antioxidants in human health and disease
Aruoma, O. I. (1998) · Journal of the American Oil Chemists' Society · doi:10.1007/s11746-998-0032-9 · Cited by 1,682
Statins as a newly recognized type of immunomodulator.
Kwak, B., Mulhaupt, F., Myit, S., & Mach, F. (2000) · Nature Medicine · doi:10.1038/82219 · Cited by 1,383
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Acetaminophen Hepatotoxicity in Alcoholics: A Therapeutic Misadventure
SEEFF, L. B., CUCCHERINI, B. A., ZIMMERMAN, H. J., ADLER, E., & BENJAMIN, S. B. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-3-399 · Cited by 424
Epigenetics, oxidative stress, and Alzheimer disease
Zawia, N. H., Lahiri, D. K., & Cardozo-Pelaez, F. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.02.006 · Cited by 337
Labbe, G., Pessayre, D., & Fromenty, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00608.x · Cited by 317
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Drug Safety Sciences and the Bottleneck in Drug Development
Watkins, P. B. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.63 · Cited by 211
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Self-citationAndrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationEASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure
Wendon, J., Cordoba, J., Dhawan, A., Larsen, F. S., Manns, M., Nevens, F., Samuel, D., Simpson, K. J., Yaron, I., & Bernardi, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.003 · Cited by 917
Spatial heterogeneity in the mammalian liver
Ben-Moshe, S., & Itzkovitz, S. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0134-x · Cited by 485
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Self-citationDrug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
Incidence and risk factors of drug‐induced liver injury
Li, X., Tang, J., & Mao, Y. (2022) · Liver International · doi:10.1111/liv.15262 · Cited by 158
Rani, J., Dhull, S. B., Rose, P. K., & Kidwai, M. K. (2024) · Phytomedicine · doi:10.1016/j.phymed.2023.155142 · Cited by 91
Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients
Devarbhavi, H., Choudhury, A. K., Sharma, M. K., Maiwall, R., Al Mahtab, M., Rahman, S., Chawla, Y. K., Dhiman, R. K., Duseja, A., Taneja, S., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000201 · Cited by 85
Drug-induced liver injury in older people
Lucena, M. I., Sanabria, J., García-Cortes, M., Stephens, C., & Andrade, R. J. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30006-6 · Cited by 77
Self-citationDrug-induced liver injury: Highlights from a review of the 2015 literature
Sarges, P., Steinberg, J. M., & Lewis, J. H. (2016) · Drug Safety · doi:10.1007/s40264-016-0427-8 · Cited by 74
Drug rechallenge following drug-induced liver injury
Hunt, C. M., Papay, J. I., Stanulovic, V., & Regev, A. (2017) · Hepatology · doi:10.1002/hep.29152 · Cited by 72
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Self-citationTeschke, R., Larrey, D., Melchart, D., & Danan, G. (2016) · Medicines · doi:10.3390/medicines3030018 · Cited by 69
Niu, H., Sanabria-Cabrera, J., Alvarez-Alvarez, I., Robles-Diaz, M., Stankevičiūtė, S., Aithal, G. P., Björnsson, E. S., Andrade, R. J., & Lucena, M. I. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105404 · Cited by 58
Self-citationBenesic, A., Rotter, I., Dragoi, D., Weber, S., Buchholtz, M.-L., & Gerbes, A. L. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.049 · Cited by 52
Beneficial effect of corticosteroids for patients with severe drug‐induced liver injury
Hu, P. F., Wang, P. Q., Chen, H., Hu, X. F., Xie, Q. P., Shi, J., Lin, L., & Xie, W. F. (2016) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12383 · Cited by 50
The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
Moreno-Torres, M., Quintás, G., & Castell, J. V. (2022) · Metabolites · doi:10.3390/metabo12060564 · Cited by 50
Zhang, L., Niu, M., Wei, A.-W., Tang, J.-F., Tu, C., Bai, Z.-F., Zou, Z.-S., Xiao, X.-H., Liu, Y.-P., & Wang, J.-B. (2020) · Archives of Toxicology · doi:10.1007/s00204-019-02595-3 · Cited by 49
Clarke, J. I., Dear, J. W., & Antoine, D. J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1160057 · Cited by 46
Li, H.-Y., Tang, Z.-M., Wang, Z., Lv, J.-M., Liu, X.-L., Liang, Y.-L., Cheng, B., Gao, N., Ji, S.-R., & Wu, Y. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.09.003 · Cited by 39
Inagaki, K., Mori, N., Honda, Y., Takaki, S., Tsuji, K., & Chayama, K. (2017) · Kanzo · doi:10.2957/kanzo.58.448 · Cited by 35
The development of a database for herbal and dietary supplement induced liver toxicity
Zhu, J., Seo, J.-E., Wang, S., Ashby, K., Ballard, R., Yu, D., Ning, B., Agarwal, R., Borlak, J., Tong, W., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102955 · Cited by 29
Self-citationCueto‐Sánchez, A., Niu, H., Álvarez‐Álvarez, I., López‐Longarela, B., Del Campo‐Herrera, E., Ortega‐Alonso, A., García‐Cortés, M., Pinazo‐Bandera, J., Sanabria‐Cabrera, J., Díaz‐Mochón, J. J., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15724 · Cited by 24
Self-citationTu, C., Niu, M., Wei, A.-W., Tang, J.-F., Zhang, L., Jing, J., Xiao, X.-H., & Wang, J.-B. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s299892 · Cited by 15
Hepatotoxicity of FDA-approved small molecule kinase inhibitors
Jiang, H., Jin, Y., Yan, H., Xu, Z., Yang, B., He, Q., & Luo, P. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1867104 · Cited by 13
Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury
Liu, Y.-H., Guo, Y., Xu, H., Feng, H., & Chen, D.-Y. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s326386 · Cited by 13
Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone
Ye, J.-H., Ho, Y.-F., On, A. W.-F., Chen, W.-W., Huang, Y.-M., Huang, W.-I., & Tang, Y.-W. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0698-5 · Cited by 10
Xiong, Y.-T., Wang, J.-F., Li, L., Bai, Z.-F., Liu, Y., Huang, A., Wang, K.-X., Fu, Y., Yang, W., Guo, C., et al. (2024) · iLIVER · doi:10.1016/j.iliver.2024.100095 · Cited by 6
DILI Differences and Similarities between the US and Europe
Toro-Ortiz, J. P., Andrade, R. J., & Pinazo-Bandera, J. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00733-x
Self-citation
Metadata
- Authors
- Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., & Lucena, M. I.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 63
- Issue
- 2
- Pages
- 503-514
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1990506447
- Cited by
- 405
- References
- 13
- FWCI
- 40.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
